MILAD BOLESS: Open Payments
NPI 1386417798 · OCALA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$326 in 15 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $221 · 2025 $326
Food & beverage: $326
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $151 |
| ABBVIE INC. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Orexo US, Inc. | 1 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $24 |
| Indivior Inc. | 1 | $18 |
Products named: ARISTADA, VIVITROL, VRAYLAR, ABILIFY MAINTENA, Auvelity, Zubsolv, ERZOFRI EXTENDED-RELEASE, SUBLOCADE.
Industry payments across FL — which companies pay providers there.
